Takeda leads the gene therapy charge in Japan

15 November 2021

Of the companies developing gene therapies in Japan, Takeda (TYO: 4502) is leading the way, according to data and analytics company GlobalData.

Takeda is at the top of the pile in terms of its activity on the deal-making front compared to others in the sector in Japan, where cell therapy and gene therapy are categorized as regenerative medicine products based on the Pharmaceuticals and Medical Devices Law implemented in 2014.

According to GlobalData’s Pharmaceutical Intelligence Center, there are three gene-modified cell therapies and two gene therapies approved in Japan, while 17 gene-modified cell therapies and 13 gene therapies are in the clinical pipeline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK